



Please find our Research on Bloomberg BRYG <GO>

30th March 2016

## BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
<b>Indices</b>			
Dow Jones	17633.11	+0.56%	+1.19%
S&P 500	2055.01	+0.88%	+0.54%
Nasdaq	4846.62	+1.67%	-3.21%
Nikkei	16878.96	-1.31%	-10.14%
Stoxx 600	336.793	+0.51%	-7.93%
CAC 40	4366.67	+0.85%	-5.83%
<b>Oil /Gold</b>			
Crude WTI	39.39	0.00	+5.89%
Gold (once)	1226.28	+0.49%	+15.43%
<b>Currencies/Rates</b>			
EUR/USD	1.11855	-0.26%	+2.97%
EUR/CHF	1.09145	+0.02%	+0.37%
German 10 years	0.142	-20.34%	-77.69%
French 10 years	0.415	-8.72%	-57.67%

### Economic releases :

Date	
30th-Mar	CNY - leading index Feb.
	JP - Industrial prod. Feb./y (-1.5% A, -1.7% E)
	DE - CPI Mar. (+0.6% E m/m)
	DE - CPI Mar. (+0.1% E y/y)
	US - ADP employment change Mar. (195K E)
	US - DOE Oil Inventories

### Upcoming BG events :

Date	
8th-Apr	VINCI (BGLuxembourg roadshow with CFO)
12th-Apr	DBV TECH. (BG Paris roadshow with CEO)
20th-Apr	REMY COINTREAU (BG Paris breakfast with CFO)
22nd-Apr	PERNOD RICARD (BG Paris roadshow with Head of IR)
28th-Apr	ORPEA (BG Luxembourg with IR)
28th-Apr	ORPEA (BG Luxembourg with IR)

### Recent reports :

Date	
29th-Mar	IPSEN Cabozantinib makes Ipsen a different story
23rd-Mar	AMOEBIA It's getting closer!
23rd-Mar	Feedback from our TMT Conference in Paris
22nd-Mar	SOPRA STERIA : Flawless integration of Steria so far
22nd-Mar	SOFTWARE AG : From value to growth
22nd-Mar	LUXOTTICA : Turbulence almost over, make the most of it!

List of our Reco & Fair Value : Please click here to download



### E.ON

**BUY, Fair Value EUR10,2 (+25%)**

#### 2016 guidance revised up thanks to gas renegotiation

The German integrated utilities group raised its 2016 earnings guidance yesterday following positive renegotiations with Gazprom on price adjustments to long-term gas supply contracts. The group is now targeting EBITDA of between EUR6.4bn and EUR6.9bn vs. EUR6-6.5bn previously and net income of EUR1.5bn and EUR1.9bn vs. EUR1.2-1.6bn previously.

### MELIA HOTELS

**BUY-Top Picks, Fair Value EUR15 (+51%)**

#### Convertible bonds: Early redemption

As anticipated and pursuant to the conditions of the issue, Melia informed the early redemption of all the convertible bonds. The conversion will be exercised between April 4th and April 14th, 2016. Already integrated in our diluted numbers, that conversion will improve significantly Melia's balance sheet with particularly a leverage ratio of below 2x (our estimate is 1.7x) compared with 3.1x (net debt/EBITDA w/o asset rotation).

### ORPEA

**BUY, Fair Value EUR76 (+5%)**

#### 2015 results: Solid even though acquisitions weighed on the margin slightly

Following FY 2015 revenue (up 22.7% reported and 5.4% lfl), results were more or less in line with expectations. EBITDAR reached EUR652m (consensus EUR655m) up 21.3% representing a margin of 27.3% down 30bp due to acquisitions, while EBITDA of EUR400m was bang in line with the consensus (EUR401m). The net result of EUR153m was slightly better (consensus EUR151m) up 12.5% and management is to propose a dividend of EUR0.90 (EUR0.87 anticipated) compared with EUR0.80 last year. In addition, the balance sheet was robust despite strong growth in the value of the real estate portfolio to over EUR3.4bn, up 23% with acquisitions in Germany, Austria and Spain. At the end of March, management expects sustained growth for 2016 with a revenue target of EUR2,720m, up 13.7% with solid profitability.

### In brief..

**CAPGEMINI, Agreement with HMRC on the transition of the Aspire contract**

**QIAGEN, Small addition to QIAGEN's portfolio**

**WIRECARD, FY16 EBITDA guidance increased**

Utilities

**E.ON**

Price EUR8.15

**2016 guidance revised up thanks to gas renegotiation**

Fair Value EUR10,2 (+25%)

**BUY**

Bloomberg	EOA GY
Reuters	EONGn.DE
12-month High / Low (EUR)	14.7 / 7.1
Market Cap (EURm)	16,304
Ev (BG Estimates) (EURm)	49,714
Avg. 6m daily volume (000)	12 869
3y EPS CAGR	

The German integrated utilities group raised its 2016 earnings guidance yesterday following positive renegotiations with Gazprom on price adjustments to long-term gas supply contracts. The group is now targeting EBITDA of between EUR6.4bn and EUR6.9bn vs. EUR6-6.5bn previously and net income of EUR1.5bn and EUR1.9bn vs. EUR1.2-1.6bn previously.

**ANALYSIS**

• **2016 guidance revised up:** The German integrated utilities group has raised its 2016 earnings guidance (*during market*) following a positive renegotiation with Gazprom on price adjustments to long-term gas supply contracts. The positive impact will still impact E.ON's earnings but in reality will affect the new entity called Uniper. Negotiations between Uniper, the fully-owned E.ON subsidiary, and Gazprom to adjust the prices of long-term gas supply contracts have led to an agreement earlier than anticipated. The agreement resolves a pending arbitration procedure between the companies. Alexander Medvedev, Deputy Chairman of the Management Committee of OAO Gazprom, Elena Burmistrova, General Director of Gazprom export LLC, and Klaus Schäfer, Chairman of Management Board of Uniper AG, signed an agreement to this effect.

• **What impacts for the group?** The agreement will enable E.ON to release some of the provisions recorded in prior years, resulting in a non-recurring positive EBITDA effect of about EUR380m in Q1 2016. The release of the remaining provisions, over several years, will result in cash outflow of circa EUR800 million, probably in Q2 2016. For E.ON, the agreement will have a non-recurring positive effect increasing E.ON's forecast range for its 2016 EBITDA from between EUR6bn and EUR6.5bn to between EUR6.4bn and EUR6.9bn. Similarly, instead of underlying net income of EUR1.2-1.6bn, E.ON now expects the range to be between EUR1.5 and EUR1.9bn.

• **Conclusion:** This contract renegotiation is clearly positive for the group, and for Uniper more precisely, although in a way it simply reflects the massive decline in commodity prices observed over the past two/three years. With this agreement, gas prices are adjusted on the basis of the group's current market conditions. Uniper has derisked its long-term gas supply contracts for coming years. We confirm our Buy rating with a FV unchanged at EUR10.2.

**VALUATION**

- At the current share price E.ON is trading at 7.8x its 2016e EBITDA and offers a 6% yield
- Buy, FV @ EUR10.2

**NEXT CATALYSTS**

- 26th April 2016: E.ON Investor Day

	1 M	3 M	6 M	31/12/15
Absolute perf.	-2.8%	-8.7%	11.4%	-8.8%
Utilities	2.8%	-5.9%	2.0%	-5.0%
DJ Stoxx 600	0.9%	-8.9%	-0.7%	-7.9%

YEnd Dec. (EURm)	2014	2015e	2016e	2017e
Sales	111,556	116,238	127,006	143,892
% change		4.2%	9.3%	13.3%
EBITDA	8,337	7,357	6,492	6,787
EBIT	4,664	3,819	3,265	3,492
% change		-18.1%	-14.5%	7.0%
Net income	-3,160	1,624	1,283	1,451
% change		NS	-21.0%	13.1%

	2014	2015e	2016e	2017e
Operating margin	4.2	3.3	2.6	2.4
Net margin	-2.8	1.4	1.0	1.0
ROE	-11.8	9.6	7.7	8.7
ROCE	8.5	10.0	8.5	8.8
Gearing	50.9	50.4	53.5	53.0

(EUR)	2014	2015e	2016e	2017e
EPS	-1.66	0.85	0.67	0.76
% change	-	NS	-21.0%	13.1%
P/E	NS	9.6x	12.1x	10.7x
FCF yield (%)	10.4%	7.3%	4.4%	7.9%
Dividends (EUR)	0.50	0.50	0.50	0.50
Div yield (%)	6.1%	6.1%	6.1%	6.1%
EV/Sales	0.6x	0.4x	0.4x	0.4x
EV/EBITDA	7.7x	6.8x	7.8x	7.6x
EV/EBIT	13.8x	13.0x	15.5x	14.7x



[Click here to download](#)



Analyst :  
 Xavier Caroen  
 33(0) 1.56.68.75.18  
 xcaroen@bryangarnier.com

Hotels

**Melia Hotels**

Price EUR9.92

**Convertible bonds: Early redemption**

Fair Value EUR15 (+51%)

BUY-Top Picks

Bloomberg	MEL SM
Reuters	MELL.MC
12-month High / Low (EUR)	13.7 / 8.4
Market Cap (EURm)	1,975
Ev (BG Estimates) (EURm)	2,450
Avg. 6m daily volume (000)	723.8
3y EPS CAGR	34.7%

As anticipated and pursuant to the conditions of the issue, Melia informed the early redemption of all the convertible bonds. The conversion will be exercised between April 4th and April 14th, 2016. Already integrated in our diluted numbers, that conversion will improve significantly Melia's balance sheet with particularly a leverage ratio of below 2x (our estimate is 1.7x) compared with 3.1x (net debt/EBITDA w/o asset rotation).

	1 M	3 M	6 M	31/12/15
Absolute perf.	1.0%	-18.2%	-17.8%	-18.6%
Travel&Leisure	-4.3%	-10.2%	1.3%	-9.6%
DJ Stoxx 600	0.9%	-8.9%	-0.7%	-7.9%

**ANALYSIS**

- Convertible bonds main characteristics:** Convertible bonds represented a total amount of EUR250m with a yield of 4.5% issued in 2013 and maturing in March 2018. With market conversion price of EUR7.32, conversion could be forced after 3 years if share price higher 30% conversion price i.e. EUR9.51. Maximum share dilution is 17.2% with current short position of around 10%.

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	1,738	1,832	1,976	2,120
% change		5.4%	7.9%	7.3%
EBITDA	293	278	316	352
EBIT	164.1	130.7	154.7	176.3
% change		-20.3%	18.3%	14.0%
Net income	36.1	47.8	80.9	99.5
% change		32.4%	69.2%	23.0%

- Debt is no longer an issue and financial costs could be improved:** Taking into account the convertible bonds, net debt on EBITDA will improve significantly from 3.1x to 1.7x based on our estimates. More, having in mind that average cost of debt was 4.4% on average in 2015 (4.8% in 2014), the group will have the opportunity to refinance at a better price due to that situation.

	2015	2016e	2017e	2018e
Operating margin	9.4	7.1	7.8	8.3
Net margin	2.1	2.6	4.1	4.7
ROE	3.1	3.2	5.1	6.1
ROCE	5.2	4.0	4.6	5.1
Gearing	58.5	28.6	29.7	28.6

**VALUATION**

- Based on our estimates and using a DCF with WACC at 6.6% taking into account our new ERP of 7% vs. 6.4% and a risk-free rate of 1.6% vs. 2%, with a beta of 0.9 and a long term growth of 2.5%, an EBIT margin of 10%, we are confirming our FV of EUR15.

(EUR)	2015	2016e	2017e	2018e
EPS	0.19	0.25	0.39	0.47
% change		26.6%	59.3%	21.0%
P/E	51.2x	40.4x	25.4x	21.0x
FCF yield (%)	5.7%	1.9%	3.1%	4.6%
Dividends (EUR)	0.03	0.06	0.07	0.07
Div yield (%)	0.3%	0.6%	0.7%	0.7%
EV/Sales	1.6x	1.3x	1.3x	1.2x
EV/EBITDA	9.4x	8.8x	7.8x	7.0x
EV/EBIT	16.7x	18.7x	16.0x	14.0x

- At the current share price, the stock is trading on 2016e EV/EBITDA of 8.8x and 7.8x for 2017e compared with an EBITDA CAGR 2015-2018 of 12.7%

**NEXT CATALYSTS**

- Q1 2016 results mid-May 2016

[Click here to download](#)



Analyst :  
 Bruno de La Rochebrochard  
 33(0) 1 56 68 75 88  
 bdelarochebrochard@bryangarnier.com

Hotels

**Melia Hotels**

Price EUR9.92

**Convertible bonds: Early redemption**

Fair Value EUR15 (+51%)

BUY-Top Picks

Bloomberg	MEL.SM
Reuters	MEL.MC
12-month High / Low (EUR)	13.7 / 8.4
Market Cap (EURm)	1,975
Ev (BG Estimates) (EURm)	2,450
Avg. 6m daily volume (000)	723.8
3y EPS CAGR	34.7%

As anticipated and pursuant to the conditions of the issue, Melia has announced the early redemption of all convertible bonds. The conversion will be exercised between April 4th and April 14th, 2016. Already integrated into our diluted numbers, the conversion will significantly improve Melia's balance sheet particularly with a leverage ratio of below 2x (our estimate is 1.7x) compared with 3.1x (net debt/EBITDA w/o asset rotation).

(	1 M	3 M	6 M	31/12/15
Absolute perf.	1.0%	-18.2%	-17.8%	-18.6%
Travel&Leisure	-4.3%	-10.2%	1.3%	-9.6%
DJ Stoxx 600	0.9%	-8.9%	-0.7%	-7.9%

**ANALYSIS**

- Main characteristics of the convertible bonds:** The convertible bonds represented a total amount of EUR250m with a yield of 4.5% issued in 2013 and maturing in March 2018. With a market conversion price of EUR7.32, conversion could be forced after three years if the share price was 30% higher than the conversion price i.e. EUR9.51. Maximum share dilution is 17.2% with current short position of around 10%.

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	1,738	1,832	1,976	2,120
% change		5.4%	7.9%	7.3%
EBITDA	293	278	316	352
EBIT	164.1	130.7	154.7	176.3
% change		-20.3%	18.3%	14.0%
Net income	36.1	47.8	80.9	99.5
% change		32.4%	69.2%	23.0%

- Debt is no longer an issue and financial costs could be improved:** Taking into account the convertible bonds, net debt on EBITDA will improve significantly from 3.1x to 1.7x based on our estimates. In addition, bearing in mind that the average cost of debt was 4.4% on average in 2015 (4.8% in 2014), the group should be able to refinance at a better price thanks to this situation.

	2015	2016e	2017e	2018e
Operating margin	9.4	7.1	7.8	8.3
Net margin	2.1	2.6	4.1	4.7
ROE	3.1	3.2	5.1	6.1
ROCE	5.2	4.0	4.6	5.1
Gearing	58.5	28.6	29.7	28.6

**VALUATION**

- Based on our estimates and using a DCF with WACC at 6.6% taking into account our new ERP of 7% vs. 6.4% and a risk-free rate of 1.6% vs. 2%, with a beta of 0.9 and a long term growth of 2.5%, an EBIT margin of 10%, we are confirming our FV of EUR15.

(EUR)	2015	2016e	2017e	2018e
EPS	0.19	0.25	0.39	0.47
% change		26.6%	59.3%	21.0%
P/E	51.2x	40.4x	25.4x	21.0x
FCF yield (%)	5.7%	1.9%	3.1%	4.6%
Dividends (EUR)	0.03	0.06	0.07	0.07
Div yield (%)	0.3%	0.6%	0.7%	0.7%
EV/Sales	1.6x	1.3x	1.3x	1.2x
EV/EBITDA	9.4x	8.8x	7.8x	7.0x
EV/EBIT	16.7x	18.7x	16.0x	14.0x

- At the current share price, the stock is trading on 2016e EV/EBITDA of 8.8x and 7.8x for 2017e compared with an EBITDA CAGR 2015-2018 of 12.7%

**NEXT CATALYSTS**

- Q1 2016 results mid-May 2016

[Click here to download](#)



**Analyst :**  
 Bruno de La Rochebrochard  
 33(0) 1 56 68 75 88  
 bdelarochebrochard@bryangarnier.com

TMT

**Capgemini**

Price EUR82.06

**Agreement with HMRC on the transition of the Aspire contract**

Fair Value EUR93 (+13%)

BUY

Bloomberg	CAP.FP
Reuters	CAPP.PA
12-month High / Low (EUR)	90.2 / 69.0
Market Cap (EURm)	14,129
Avg. 6m daily volume (000)	687.8

	1 M	3 M	6 M	31/12/15
Absolute perf.	7.0%	-4.7%	5.8%	-4.1%
Softw.& Comp.				
SVS	2.7%	-3.6%	17.4%	-2.9%
DJ Stoxx 600	0.9%	-8.9%	-0.7%	-7.9%
	2015	2016e	2017e	2018e
P/E	17.6x	15.3x	13.9x	12.9x
Div yield (%)	1.6%	1.8%	1.9%	2.1%

**ANALYSIS**

- **This morning Capgemini announced an agreement with the UK's HMRC on the phased transition of the Aspire contract.** Capgemini will continue as a strategic supplier to HMRC notably in application development and management services through to June 2020. In support of HMRC's decision to take greater control of IT, Capgemini will transition a number of services between now and June 2017. As part of its continuing role as a strategic supplier in applications management services in areas such as SAP, analytics and testing, Capgemini will also contribute to HMRC's digital transformation program.
- **Not really surprising.** The Aspire contract, according to our estimates, accounts for 4% of revenues. At our TMT conference on 11<sup>th</sup> March, the company confirmed there would be no "step effect" to revenues on it as the transition will take time as it is sensitive. We take the assumption that, by 2018 Capgemini will keep half of the revenues currently generated with HMRC, i.e. 2%. On the services to be re-insourced by HMRC on Aspire, we consider that the negative impact to revenues will amount 0.7% per year on average over 2015-2018.

**VALUATION**

- Capgemini's shares are trading at est. 10.7x 2016 and 9.1x 2017 EV/EBIT multiples.
- Net debt on 31<sup>st</sup> December 2015 was EUR1,747m (net gearing: 25%).

**NEXT CATALYSTS**

Q1 16 sales on 27<sup>th</sup> April before markets open. [Click here to download](#)

Gregory Ramirez, [gramirez@bryangarnier.com](mailto:gramirez@bryangarnier.com)

## Healthcare

**QIAGEN**

Price EUR19.38

## Small addition to QIAGEN's portfolio

Fair Value EUR22 vs. EUR24 (+14%)

NEUTRAL

Bloomberg	QIA GR
Reuters	QGEN.DE
12-month High / Low (EUR)	26.0 / 17.8
Market Cap (EURm)	4,644
Avg. 6m daily volume (000)	426.1

	1 M	3 M	6 M	31/12/15
Absolute perf.	-1.6%	-23.4%	-14.3%	-22.9%
Healthcare	-2.7%	-13.6%	-6.4%	-12.8%
DJ Stoxx 600	0.9%	-8.9%	-0.7%	-7.9%

	2015	2016e	2017e	2018e
P/E	20.6x	19.8x	18.4x	16.6x
Div yield (%)	NM	NM	NM	NM

## ANALYSIS

- QIAGEN has announced its intention to acquire Danish company Exiqon (EXQ:DC) for slightly less than USD100m or DKK18.00 per share (42% premium on yesterday's closing price, DKK/USD=0.15, x5 sales). Both boards have recommended the acquisition which is now conditional on the agreement of the Danish Financial Supervisory Authority.
- Exiqon is a small but nice addition to QIAGEN's portfolio which should enable the group to expand its expertise in NGS target enrichment. The Danish company recorded about USD20m last year. After taking into account overlap with QIAGEN's business, Exiqon should add USD15m growing in the low to mid-teens, to QIAGEN's topline which should grow at 5% CER in 2016 (BGe USD1,324m for 2016). This acquisition should have no impact in terms of margins and EPS.
- Interestingly, Exiqon's products are used by researchers in the academic or biopharma fields to study the relation between gene activity and cancer development. Moreover, we believe that collaboration agreements that QIAGEN has with pharma and diagnostic companies to develop molecular tests for the untapped oncology detection market could benefit from products developed by Exiqon with some products to be used with liquid biopsy. As a reminder, we estimate that Personalised Healthcare (PHC) represents 10% of QIA's turnover, set to rise to 16% of sales and growing at a double-digit rate

## VALUATION

- The acquisition of Exiqon has no impact on our Fair Value. We reiterate our NEUTRAL rating as significant investments in S&M to support the launch of the GeneReader could impair the group's margins in this year, and are likely to delay until H2 the effect of reinternalizing QuantiFERON-TB.
- Changes in our risk free rate and equity risk premium assumptions which now stand at 1.6% and 7% respectively vs. 2% and 6.4% previously, have prompted a EUR2 decline in our Fair Value

## NEXT CATALYSTS

- 27th April 2016: Q1 results

[Click here to download](#)Hugo Solvet, [hsolvet@bryangarnier.com](mailto:hsolvet@bryangarnier.com)



TMT

**Wirecard**

Price EUR31.76

**FY16 EBITDA guidance increased****Fair Value EUR52 (+64%)****BUY-Top Picks**

Bloomberg	WDI GR
Reuters	WDIG.DE
12-month High / Low (EUR)	47.4 / 31.2
Market Cap (EURm)	3,924
Avg. 6m daily volume (000)	826.5

	1 M	3 M	6 M	31/12/15
Absolute perf.	-13.1%	-31.7%	-23.4%	-31.7%
Softw.& Comp.				
SVS	2.7%	-3.6%	17.4%	-2.9%
DJ Stoxx 600	0.9%	-8.9%	-0.7%	-7.9%
	2014	2015e	2016e	2017e
P/E	31.5x	24.4x	17.4x	13.7x
Div yield (%)	0.4%	0.4%	0.4%	0.5%

**ANALYSIS**

- Wirecard Management Board has increased the EBITDA guidance for the FY16 from EUR280m to EUR 300m to a bandwidth of between EUR290m to EUR310m.
- The reasons for the guidance increase are a strong start of the operating business, the newly consolidated subsidiaries in Brazil and Romania and additionally a higher expected EBITDA contribution from the new Indian business.
- Only in the first three months of 2016 the acquired Indian subsidiaries were able to increase the number of internet-based retail agents by 15% in comparison to the end of 2015.
- As a reminder, we have FY16e revenue of EUR1,016.3m (+20.3% lfl), EBITDA of EUR306.4m (margin of 30.1%, +60bp) and current EBIT of EUR270.8m (margin of 26.6%, +80bp). And we forecast a net cash position of EUR403.4m at end-2016e.

**VALUATION**

- Buy rating and FV of EUR52 maintained.** The stock is in our Q1 Top Pick List.
- Over FY16e:** P/E of 17.4x vs. rest. EPS growth of +40.7%.

**NEXT CATALYSTS**

- FY 2015 financial statements:** 7th April 2016.

[Click here to download](#)Richard-Maxime Beaudoux, [rmbeaudoux@bryangarnier.com](mailto:rmbeaudoux@bryangarnier.com)





<b>London</b>	<b>Paris</b>	<b>New York</b>	<b>Geneva</b>	<b>New Delhi</b>
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the Financial Conduct	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by	Authority (FCA) and l Autorité de		Regulated by the	Fax +91 11 2621 9062
the Financial Conduct Authority	Contrôle prudentiel et de resolution		FINMA	
(FCA)	(ACPR)			



## BRYAN, GARNIER & CO

### Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

### Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

### Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

### Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research.

These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

### Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

### Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....